References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
Hiligsmann, Mickaël ULg; Vanoverberghe, Marie ULg; Neuprez, Audrey ULg et al

in Expert Review of Pharmacoeconomics & Outcomes Research (2010), 10(4), 359-366

Strontium ranelate has recently been introduced for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This study aims to review the published cost-effectiveness ... [more ▼]

Strontium ranelate has recently been introduced for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This study aims to review the published cost-effectiveness literature pertaining to strontium ranelate. Six studies were identified: two in United Kingdom, two in Belgium and two in Sweden. The findings were consistent across the literature, suggesting that strontium ranelate is a cost-saving drug for women with osteoporosis aged over 80 years of age, and it is a cost-effective treatment compared with no treatment for osteoporotic women aged over 70 years and for younger women with clinical risk factors for fragility fracture. Strontium ranelate was also shown to be cost-effective compared with branded risedronate in osteoporotic women over 75 years. Further analyses are required to assess effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men. [less ▲]

Detailed reference viewed: 57 (2 ULg)
Full Text
Peer Reviewed
See detailRehabilitation in osteoarthritis
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg; Croisier, Jean-Louis ULg et al

in Therapy (2010), 7(6), 669-674

Detailed reference viewed: 37 (15 ULg)
Full Text
Peer Reviewed
See detailLarge review finds no clinically important effect of glucosamine or chondroitin on pain in people with osteoarthritis of the knee or hip but results are questionable and likely due to heterogeneity
Bruyère, Olivier ULg

in Evidence-Based Medicine (2010)

Context Treatment of osteoarthritis with unspecifi c symptomatic agents is not satisfactory and burdened with safety issues. The use of glucosamine and/or chondroitin as diseasemodifying agents is ... [more ▼]

Context Treatment of osteoarthritis with unspecifi c symptomatic agents is not satisfactory and burdened with safety issues. The use of glucosamine and/or chondroitin as diseasemodifying agents is increasingly popular, despite conflicting clinical trial evidence with the many available products. Wandel and colleagues produced a systematic review and a meta-analysis with relatively new statistical methods. [less ▲]

Detailed reference viewed: 288 (12 ULg)
Full Text
Peer Reviewed
See detailBoth weight-bearing and non–weightbearing exercise improved function in patients with knee osteoarthritis
Bruyère, Olivier ULg

in Evidence-Based Medicine (2009), 14(6), 178

Detailed reference viewed: 45 (2 ULg)
Full Text
Peer Reviewed
See detailRationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®
Neuprez, Audrey ULg; Johansson, H.; Kanis, J. et al

in Revue Médicale de Liège (2009), 64(12), 612-619

RESUME : Cette étude a pour but d’adapter à la population belge l’algorithme FRAX® récemment publié par l’Organisation Mondiale de la Santé (OMS) et permettant de calculer, dans les deux sexes, le risque ... [more ▼]

RESUME : Cette étude a pour but d’adapter à la population belge l’algorithme FRAX® récemment publié par l’Organisation Mondiale de la Santé (OMS) et permettant de calculer, dans les deux sexes, le risque absolu de fractures ostéoporotiques, à 10 ans. Nous nous sommes attachés à quantifier le risque fracturaire correspondant aux critères actuellement appliqués, en Belgique, pour le remboursement des médicaments de l’ostéoporose et à identifier les situations cliniques correspondant à une probabilité équivalente de fracture. Les probabilités fracturaires ont été calculées, à partir des incidences de fractures et de décès publiées, pour la population belge. Ces probabilités prennent en considération l’âge, le sexe, l’existence de facteurs cliniques de risque (FCR) et la densité minérale osseuse (DMO), mesurée au niveau de la zone propre du col fémoral. L’algorithme FRAX® permet d’identifier différents scénarios d’intervention, en Belgique, correspondant à un risque fracturaire identique ou supérieur à celui servant de base aux critères actuels de remboursement des médicaments. Il est donc possible de recommander une modification des attitudes actuelles, délaissant une stratégie basée sur une évaluation dichotomique de la DMO, au profit d’une intégration progressive des FCR qui permettra, in fine, une meilleure identification des patients à risque accru de fracture. Cette approche devra être substantiée par des analyses pharmaco-économiques appropriées. [less ▲]

Detailed reference viewed: 218 (20 ULg)
See detailDonnées récentes sur les traitements symptomatiques à action lente dans l'arthrose
Bruyère, Olivier ULg

Conference (2009, November 18)

Detailed reference viewed: 13 (0 ULg)
See detailQuoi de neuf dans la prise en charge de l'ostéoporose
Bruyère, Olivier ULg

Conference (2009, November 14)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Bruyère, Olivier ULg et al

in Arthritis and Rheumatism (2009, October), 60(number 10 (suppl.)), 328

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of nonadherence with osteoporosis medications
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Bruyère, Olivier ULg et al

in Value in Health (2009, October), 12(7), 444

Detailed reference viewed: 42 (13 ULg)
See detailNon-pharmacological strategy to decrease risk of fall in the elderly
Bruyère, Olivier ULg

Conference (2009, March 28)

Detailed reference viewed: 14 (9 ULg)
See detailVitamin D : epidemiologic aspect of the deficiency
Bruyère, Olivier ULg

Conference (2009, March 27)

Detailed reference viewed: 10 (0 ULg)
Peer Reviewed
See detailNew data for the management of osteoarthritis
Bruyère, Olivier ULg

Conference (2009, March 19)

Detailed reference viewed: 7 (0 ULg)
See detailUtilisation des glucosamines dans l'arthrose
Bruyère, Olivier ULg

Conference (2009, March 12)

Detailed reference viewed: 23 (5 ULg)
Full Text
Peer Reviewed
See detailTreatment of osteoarthritis with glucosamine sulftate: from clinical to economic data.
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2009, March), 20(Suppl.1), 182

Detailed reference viewed: 27 (5 ULg)